Substance / Medication

Cabozantinib

Overview

Active Ingredient
cabozantinib
RxNorm CUI
1363268

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
3
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis, and retrospective study.
Eswaran Harish, Kasthuri Rohan R, Bendapudi Pavan K et al. · Blood Adv · 2026
PMID: 41061198Meta-AnalysisFull text (PMC)
Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Gross-Goupil Marine, Bodnar Lubomir, Campbell Matthew T et al. · Clin Genitourin Cancer · 2024
PMID: 38101983Meta-Analysis
Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis.
Su Jingyang, Ni Cui, Wu Yuqian et al. · Expert Rev Anticancer Ther · 2024
PMID: 38551185Meta-Analysis
Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.
Su Jingyang, Zhang Jialin, Wu Yuqian et al. · Front Pharmacol · 2024
PMID: 38694912Meta-AnalysisFull text (PMC)
Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.
Zago Elena, Galluzzo Antonio, Pradella Silvia et al. · Endocrine · 2024
PMID: 37851242Meta-AnalysisFull text (PMC)
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.
Graham Jeffrey, Vogel Arndt, Cheng Ann-Lii et al. · Cancer Treat Rev · 2022
PMID: 36037792Meta-Analysis
A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?
Bersanelli Melissa, Buti Sebastiano, Ghidini Antonio et al. · Anticancer Drugs · 2020
PMID: 31917698Meta-Analysis
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden Paul, Carroll Christopher, Hamilton Jean et al. · Health Technol Assess · 2019
PMID: 30821231Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cabozantinib (substance)
SNOMED CT
718844003
UMLS CUI
C3181682
RxNorm CUI
1363268

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.